Vertex (VRTX) announces positive week 36 interim analysis results for primary and all secondary endpoints in the rainier phase 3 trial of povetacicept in adults with IGA nephropathy
Importance
Level 1
- To complete BLA for povetacicept by end of March for potential U.S. accelerated approval.
- Povetacicept was generally safe and well tolerated
#VERTEX PHARMACEUTICALS INC#VRTX.US#EQUITIES#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#VRTX#US EQUITIES